FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196508076> ?p ?o ?g. }

• W3196508076 abstract "Direct-acting oral anticoagulants (DOACs) have relatively recently been licensed for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (AF) and have replaced warfarin as the first line agent of choice. The aim of this research was to determine prescribers' views and experiences of the use of DOACs for the management of non-valvular AF. The first phase was a PROSPERO-registered systematic review of clinicians' views and experiences of DOACs for the management of non-valvular atrial fibrillation. Ten studies were identified. In those studies reporting clinician preference, DOACs were first choice over warfarin in naive patients, based on perceptions of evidence that DOACs had effectiveness equivalent or superior to warfarin and were also superior in safety. Other advantageous factors were in those with an unstable International Normalized Ratio and who were likely to miss appointments. There were, however, concerns relating to management of over-anticoagulation and experiences of observed bleeding rates. In addition to the lack of studies, none of the studies had used theory in the development of the data collection tools or analysis, indicating a gap in the literature. The second phase was a cross-sectional survey of prescriber's views, behaviours and experiences related to prescribing DOACs for the management of non-valvular AF. The survey was conducted in NHS Highland, inviting all medical and non-medical prescribers to participate. Items on potential influences on DOAC prescribing were based on the Theoretical Domains Framework (TDF). Principal component analysis (PCA) of the TDF items gave four components. Component scores were positive for (i) role of professionals, their knowledge and skills and (ii) influences on prescribing. There did, however, appear to be issues in switching from warfarin to DOACs or from one DOAC to another. Scores were more neutral for (iii) consequences of prescribing and (iv) monitoring for safety and effectiveness. There were low levels of agreement for statements relating to DOACs being more effective, safer and cost-effective than warfarin. There were similar responses around the complexity of bleeding management and detection of over and under-anticoagulation. Less experienced prescribers were statistically significantly more positive than more experienced prescribers in terms of the consequences of prescribing (p < 0.05). Content analysis of the responses to the open questions identified that the overwhelming perceived benefit was the absence of need for INR monitoring, with the main limitations being the lack of a suitable reversal agent and ability to monitor anticoagulation status.Given the updated recommendations of Healthcare Improvement Scotland (HIS) to use edoxaban first line, the final phase was a cross-sectional survey of prescriber's views, behaviours and experiences related to prescribing edoxaban for the management of non-valvular AF. Responses were received from 103 prescribers in NHS Highland. While almost all respondents had been encouraged to implement this recommendation of prescribing edoxaban, less than one third had either switched patients from warfarin or other DOACs to edoxaban. The following three PCA components identified in the previous survey were applied to the TDF determinants: the role of professionals, their knowledge and skills; influences on prescribing; and consequences of prescribing. While component scores for the first two components were positive, the scores for consequences of prescribing were more neutral. Although a number of respondents described edoxaban (and other DOAC) related adverse drug reactions (ADRs), very few had submitted a Yellow Card report to the Medicines and Healthcare products Regulatory Agency (MHRA). Content analysis of the responses to the open questions identified benefits and limitations similar to the previous survey. This doctoral research has generated original findings in terms of DOACs views, experiences and behaviours related to management of non-valvular AF. There is merit in reviewing the local and national guidelines, particularly in relation to switching and awareness of the evidence base. Attention should be paid to the literature on guideline implementation." @default.
• W3196508076 created "2021-09-13" @default.
• W3196508076 creator A5072978465 @default.
• W3196508076 date "2020-06-30" @default.
• W3196508076 modified "2023-09-27" @default.
• W3196508076 title "Investigating prescribers' experiences of direct-acting oral anticoagulants for the management of nonvalvular atrial fibrillation." @default.
• W3196508076 cites W122320840 @default.
• W3196508076 cites W135528526 @default.
• W3196508076 cites W1492284495 @default.
• W3196508076 cites W1513897361 @default.
• W3196508076 cites W1524473814 @default.
• W3196508076 cites W1533082284 @default.
• W3196508076 cites W1537923806 @default.
• W3196508076 cites W1551764987 @default.
• W3196508076 cites W1556578540 @default.
• W3196508076 cites W1561288333 @default.
• W3196508076 cites W1591205163 @default.
• W3196508076 cites W1605824561 @default.
• W3196508076 cites W1856642343 @default.
• W3196508076 cites W1924618820 @default.
• W3196508076 cites W1964172790 @default.
• W3196508076 cites W1965067262 @default.
• W3196508076 cites W1969321932 @default.
• W3196508076 cites W1973377496 @default.
• W3196508076 cites W1975493453 @default.
• W3196508076 cites W1977775666 @default.
• W3196508076 cites W1989528006 @default.
• W3196508076 cites W1996847696 @default.
• W3196508076 cites W1997410866 @default.
• W3196508076 cites W2002687613 @default.
• W3196508076 cites W2007948514 @default.
• W3196508076 cites W2009890917 @default.
• W3196508076 cites W2015365539 @default.
• W3196508076 cites W2019461830 @default.
• W3196508076 cites W2019792456 @default.
• W3196508076 cites W2025170215 @default.
• W3196508076 cites W2025903694 @default.
• W3196508076 cites W2031831083 @default.
• W3196508076 cites W2046152609 @default.
• W3196508076 cites W2048189471 @default.
• W3196508076 cites W2062067657 @default.
• W3196508076 cites W2066466450 @default.
• W3196508076 cites W2069353376 @default.
• W3196508076 cites W2069558717 @default.
• W3196508076 cites W2069793824 @default.
• W3196508076 cites W2070058967 @default.
• W3196508076 cites W2072091244 @default.
• W3196508076 cites W2075535107 @default.
• W3196508076 cites W2079283960 @default.
• W3196508076 cites W2080178169 @default.
• W3196508076 cites W2082217186 @default.
• W3196508076 cites W2083029092 @default.
• W3196508076 cites W2093252196 @default.
• W3196508076 cites W2096881551 @default.
• W3196508076 cites W2097941232 @default.
• W3196508076 cites W2099903944 @default.
• W3196508076 cites W2106374332 @default.
• W3196508076 cites W2106905614 @default.
• W3196508076 cites W2107262559 @default.
• W3196508076 cites W2107858339 @default.
• W3196508076 cites W2114701438 @default.
• W3196508076 cites W2116332230 @default.
• W3196508076 cites W2116567300 @default.
• W3196508076 cites W2119757584 @default.
• W3196508076 cites W2121394112 @default.
• W3196508076 cites W2122838852 @default.
• W3196508076 cites W2127516104 @default.
• W3196508076 cites W2135412352 @default.
• W3196508076 cites W2138426988 @default.
• W3196508076 cites W2138664283 @default.
• W3196508076 cites W2142225512 @default.
• W3196508076 cites W2146186573 @default.
• W3196508076 cites W2146380789 @default.
• W3196508076 cites W2148873261 @default.
• W3196508076 cites W2150104072 @default.
• W3196508076 cites W2154541062 @default.
• W3196508076 cites W2155662067 @default.
• W3196508076 cites W2157968254 @default.
• W3196508076 cites W2159177038 @default.
• W3196508076 cites W2159466611 @default.
• W3196508076 cites W2160643014 @default.
• W3196508076 cites W2161010895 @default.
• W3196508076 cites W2161054439 @default.
• W3196508076 cites W2162242768 @default.
• W3196508076 cites W2168936824 @default.
• W3196508076 cites W2172068010 @default.
• W3196508076 cites W2216829977 @default.
• W3196508076 cites W2260643844 @default.
• W3196508076 cites W2265324829 @default.
• W3196508076 cites W2342268576 @default.
• W3196508076 cites W2466926363 @default.
• W3196508076 cites W2481478678 @default.
• W3196508076 cites W2483874199 @default.
• W3196508076 cites W2509795914 @default.
• W3196508076 cites W2515923010 @default.
• W3196508076 cites W2551359113 @default.
• W3196508076 cites W2552137807 @default.
• W3196508076 cites W2555550897 @default.
• W3196508076 cites W2559641249 @default.
• W3196508076 cites W2580605101 @default.

• next